From the beginning, in 1998, Aegis set its sights on the unsatisfied demand for high-end outpatient treatment of opioid addiction, especially as it relates to addiction to prescribed medications. While the majority of NTPs focused their treatment on traditional heroin addicts, there remained very limited services offered to the new, fast-growing higher socio-economic background population.
For the most part, this disparity between the need for high-quality patient-care and the paltry supply available to this new type of patient (i.e., white collar), was the result of the antiquated regulations and fee structures that governed this industry. Despite significant scientific and clinical developments, and cultural and demographical changes, the government and its regulations have lagged 10 - 20 years behind.
Most concerning is the fact that these regulations and fee structure foster a system focused on process rather than result orientation; a system that is paper- instead of patient centered. This fact is evidenced by the fact that established rates are entirely indifferent to the quality of care or clinical outcomes. Unfortunately, NTP providers were faced with a choice between pursuing higher clinical standards and better clinical outcomes and compromising their profitability, or vice versa, giving profitability a priority over their "Product."
Considering the above-mentioned market analysis, Aegis chose to establish good will as its primary financial goal. This was done in anticipation of a full return on its investment in future years, based on growing our market share and income. Such growth would be generated by future penetration into non-traditional market segments, and secured by Aegis’ superior know-how, practices and standards.
As a result of its business plan and decision to set equity and market value as its primary financial goals, Aegis has repeatedly re-invented itself and re-engineered its clinical tools and scope of treatment over the last twelve years. In particular, Aegis has relentlessly pursued ever higher rates of clinical success (i.e. successful patient recovery). Further, it was necessary to create a "main-stream" treatment environment that would overcome the substantial stigma associated with NTPs and AOD Programs.
As a result of its efforts, Aegis was able to achieve many of its objectives over the last two to three years (including unprecedented clinical rates of success, and rapid enhancement of its financial performance.) Aegis attributes these accomplishments to the following: